About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Schizophrenia Clinical Trials in New York | 64 Studies

Clinical Trials SchizophreniaNew York

Schizophrenia Clinical Trials in New York

Find 64 clinical trials for schizophrenia near New York, New York. Connect with research centers in your area.

All Schizophrenia trials nationwide All trials in New York

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 21-40 of 64 trials

CompletedA Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic MedicationThe purpose of this study was to evaluate the efficacy of ASP4345 on cognitive impairment compared to placebo using change from baseline in MATRICS Consensus Cognitive Battery…NCT03557931·Cerritos, California and 26 others

Schizophrenia Trials in Other Cities

Los Angeles Chicago Houston Phoenix Philadelphia San Antonio

Data from ClinicalTrials.govTerms

RecruitingEffectiveness of Motivation Skills Training (MST)This study will take place at four outpatient clinics serving adults with serious mental illness.NCT05805397·New York, New York and 1 other

CompletedTreatment of Behavioral Symptoms in Alzheimer's DiseaseThe optimal strategy for the treatment of behavioral complications in patients with probable Alzheimer's disease (AD) remains unclear.NCT00009217·New York, New York

CompletedA Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of SchizophreniaThis is a Phase 3, 6-week, randomized, double-blind, placebo-controlled, multicenter, outpatient study in subjects with schizophrenia with an inadequate response to their current…NCT05145413·Phoenix, Arizona and 165 others

WithdrawnNRX-1074 in Early Course SchizophreniaThis study seeks to examine the effectiveness of NRX-1074 in the treatment of negative symptoms and cognition in schizophrenia compared to other agents at the glycine site which…NCT02603458·Boston, Massachusetts and 1 other

CompletedHippocampal Memory Circuits in DelusionsThis study will investigate dentate gyrus (DG) and hippocampal CA3 sub field function, using the pattern separation paradigm, as reflected by the difference in brain activation in…NCT03822910·New York, New York and 2 others

CompletedEffects of Risperdal Consta on Ability to Benefit From Social Skills Training in SchizophreniaThe specific aim of this study is to determine whether the new, long-acting, form of risperidone, Risperdal Consta, improves the ability of schizophrenia patients to benefit from…NCT00148083·Chicago, Illinois and 1 other

TerminatedMEtformin and Lorcaserin for WeighT Loss in SchizophreniaPurpose: The purpose of this study is to test new pharmacologic strategies for weight loss in patients with schizophrenia, a population for which no current weight-loss treatments…NCT02796144·Augusta, Georgia and 3 others

CompletedA Study to Evaluate Efficacy and Safety of Bitopertin in Participants With Persistent, Predominant Negative Symptoms of SchizophreniaThis Phase 3, multi-center, randomized, double blind, parallel-group, placebo-controlled study will evaluate the efficacy and safety of RO4917838 (bitopertin) in participants with…NCT01192880·Costa Mesa, California and 102 others

CompletedDeveloping Clinical Tools to Communicate Genetic Risk for Individuals Who Are Clinical High Risk for PsychosisWhile great strides are being made in identifying early signs that place people at a 'high risk state' for different illness conditions, at the same time, advances are being made…NCT04325568·New York, New York

CompletedClinical Trial of BI 425809 Effect on Cognition and Functional Capacity in SchizophreniaThe objective of the study is to investigate the efficacy, safety and pharmacokinetics of four different doses of BI 425809 once daily compared to placebo given for 12 weeks in…NCT02832037·Garden Grove, California and 80 others

CompletedSafety Study of ORG 34517 for Major Depression With Psychotic FeaturesPatients suffering from Major Depressive Disorder with Psychotic features who have received no changes in their medications in the previous two weeks will receive "usual"…NCT00226278·New York, New York

CompletedRemediation of Auditory Recognition in Schizophrenia With tDCSThe purpose of this study is to determine whether transcranial direct current stimulation (tDCS), when combined with different forms of computer based training, improves the…NCT02869334·New York, New York

CompletedThe Role of Dysmyelination in Cognitive Impairment of Psychotic Spectrum DisordersThis is a single center study that uses both between-group comparisons and correlational analyses to establish biomarkers of dysmyelination and cognitive impairment in Psychotic…NCT03166098·New York, New York

TerminatedA Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With SchizophreniaThe primary purpose of this study is to assess the long-term safety and tolerability of oral emraclidine in adult participants with schizophrenia.NCT05443724·Phoenix, Arizona and 84 others

CompletedAripiprazole Used as Dual Therapy in the Treatement of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder.A Multicenter, Double-blind 16 Week Study on the augmentation of atypical antipsychotic with Aripiprazole in patients with Schizophrenia with inadequate response to antipsychotic…NCT00325689·Little Rock, Arkansas and 47 others

TerminatedITI-007 (Lumateperone Tosylate) for SchizophreniaThe purpose of this study is to offer open label ITI-007 treatment to patients who poorly respond or poorly tolerate approved medications.NCT03817528·New York, New York

CompletedAntipsychotic Discontinuation in Alzheimer's DiseaseIn patients with Alzheimer's disease (AD) who respond to antipsychotic treatment of psychosis and/or agitation/aggression, the relapse risk after discontinuation is not…NCT00417482·Tuscaloosa, Alabama and 6 others

RecruitingStudy to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic MedicationsEvaluate the efficacy, as well as safety and pharmacokinetics, of Roluperidone in improving the negative symptoms of schizophrenia in adult subjects in Phase A of study, followed…NCT07565428·Bellflower, California and 12 others

CompletedA United States Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major DepressionCorlux (mifepristone) is a new medication that modulates the body's use of a hormone called cortisol.NCT00128479·Little Rock, Arkansas and 43 others

PreviousPage 2 of 4Next

Other Conditions in New York

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia